Table 10.

CG anti-respiratory virus activities in clinical studies. (BID, twice a day; RSV, respiratory syncytial virus).

CG Type	Virus Type	Experimental Model	Dose	Antiviral Assay	Effects	Ref
ι-CG (Coldmaris)	Respiratory viruses (influenza, parainfluenza, coronavirus, rhinoviruses, and human metapneumovirus)	35 human subjects, nasal spray, symptom scores	0.12%	Measure viral loads in nasal lavages	Lowered symptom scores and viral loads, lowered proinflammatory cytokines	[105]
ι-CG (Coldmaris)	Respiratory viruses (influenza, parainfluenza, coronavirus, RSV, rhinoviruses, and human metapneumovirus)	213 young human subjects, nasal spray, symptom scores	0.12%	Measure viral loads in nasal lavages	Lowered viral loads but no effects on symptom scores	[106]
ι-CG (Coldmaris)	Respiratory viruses (influenza, parainfluenza, coronavirus, RSV, rhinoviruses, and human metapneumovirus)	211 patients intranasal spray	0.12%	Measure viral loads in nasal lavages	Reduced duration of disease, alleviation of symptom, and reduced viral titers	[107]
ι-CG	Rhinovirus, coronavirus, and influenza A virus	254 human subjects with nasal spray	0.12% TID for 7 days	Nasal lavage sample	Reduced duration of disease, increased viral clearance, and reduced relapses of symptom	[108]
ι-CG	Rhinovirus, coronavirus, and influenza A virus	200 human subjects with nasal spray	0.12% QID for 4–10 days	Nasal lavage sample	No difference in total symptom scores and more effective in coronavirus	[109]